FLIP: A flop for execution signals

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 151-155

  Subramaniam, Kothandharaman ^a   Hirpara, Jayshree L ^a,b   Tucker Kellogg, Lisa ^c,d,e   Tucker Kellogg, Greg ^e   Pervaiz, Shazib ^a,b,c,e,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Apoptosis; Cancer; CFLIP

Indexed keywords

FLICE INHIBITORY PROTEIN;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL METABOLISM; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC ORGANIZATION; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84876094622     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.005     Document Type: Review

References (66)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
2. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 1999, 17(9):2941-2953.
3. Patel M.P., et al. Targeting the Bcl-2. Curr. Opin. Oncol. 2009, 21(6):516-523.
4. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets 2008, 12(4):463-476.
5. Wajant H. Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy. Mol. Interv. 2003, 3(3):124-127.
6. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25(34):4798-4811.
7. Barnhart B.C., Alappat E.C., Peter M.E. The CD95 type I/type II model. Semin. Immunol. 2003, 15(3):185-193.
8. Scott F.L., et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009, 457(7232):1019-1022.
9. Scaffidi C., et al. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999, 274(3):1541-1548.
10. Micheau O. Cellular FLICE-inhibitory protein: an attractive therapeutic target?. Expert Opin. Ther. Targets 2003, 7(4):559-573.
11. Safa A.R., Day T.W., Wu C.H. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug. Targets 2008, 8(1):37-46.
12. Yu J.W., Shi Y. FLIP and the death effector domain family. Oncogene 2008, 27(48):6216-6227.
13. Hainsworth A.H., et al. Expression of cellular FLICE inhibitory proteins (cFLIP) in normal and traumatic murine and human cerebral cortex. J. Cereb. Blood Flow. Metab. 2005, 25(8):1030-1040.
14. Piggott L., et al. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Res. 2011, 13(5):R88.
15. Luo A., et al. Short hairpin RNA targeting c-FLIP sensitizes human cervical adenocarcinoma Hela cells to chemotherapy and radiotherapy. Cancer Lett. 2008, 271(2):323-332.
16. Safa A.R., Pollok K.E. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel) 2011, 3(2):1639-1671.
17. Chandrasekaran Y., et al. Influence of TRP53 status on FAS membrane localization, CFLAR (c-FLIP) ubiquitinylation, and sensitivity of GC-2spd (ts) cells to undergo FAS-mediated apoptosis. Biol. Reprod. 2006, 74(3):560-568.
18. Wethmar K., Smink J.J., Leutz A. Upstream open reading frames: molecular switches in (patho)physiology. Bioessays 2010, 32(10):885-893.
19. Caprioli F., et al. Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Gut 2008, 57(12):1674-1680.
20. Borrelli S., et al. P63 regulates the caspase-8-FLIP apoptotic pathway in epidermis. Cell Death Differ. 2009, 16(2):253-263.
21. Salon C., et al. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). Cell Death Differ. 2006, 13(2):260-272.
22. Gao S., et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J. Mol. Endocrinol. 2006, 36(3):463-483.
23. Bartke T., et al. P53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001, 20(5):571-580.
24. Ricci M.S., et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol. 2004, 24(19):8541-8555.
25. Li W., Zhang X., Olumi A.F. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res. 2007, 67(5):2247-2255.
26. Zhang J., et al. Cyclic AMP inhibits JNK activation by CREB-mediated induction of c-FLIP(L) and MKP-1, thereby antagonizing UV-induced apoptosis. Cell Death Differ. 2008, 15(10):1654-1662.
27. Kaunisto A., et al. PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ. 2009, 16(9):1215-1226.
28. Poukkula M., et al. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J. Biol. Chem. 2005, 280(29):27345-27355.
29. Wang L., et al. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J. Immunol. 2008, 180(5):3072-3080.
30. Bai J., Cederbaum A.I. Catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents by accelerating the degradation of p53. J. Biol. Chem. 2003, 278(7):4660-4667.
31. Kauh J., et al. C-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 2010, 5(4):e10376.
32. Chen F., et al. Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol. Rep. 2010, 23(5):1457-1462.
33. Irmler M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388(6638):190-195.
34. Li Z., et al. Casper/c-FLIP is physically and functionally associated with NF-kappaB1 p105. Biochem. Biophys. Res. Commun. 2003, 309(4):980-985.
35. Nakajima A., et al. An antiapoptotic protein, c-FLIPL, directly binds to MKK7 and inhibits the JNK pathway. EMBO J. 2006, 25(23):5549-5559.
36. Zhang L., Gallagher P.J. Mind bomb 1 regulation of cFLIP interactions. Am. J. Physiol. Cell Physiol. 2009, 297(5):C1275-C1283.
37. Kim Y.Y., et al. Long form of cellular FLICE-inhibitory protein interacts with Daxx and prevents Fas-induced JNK activation. Biochem. Biophys. Res. Commun. 2003, 312(2):426-433.
38. Chang L., et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006, 124(3):601-613.
39. Moubarak R.S., et al. The death receptor antagonist FLIP-L interacts with Trk and is necessary for neurite outgrowth induced by neurotrophins. J. Neurosci. 2010, 30(17):6094-6105.
40. Kataoka T., et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 2000, 10(11):640-648.
41. Kataoka T., Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol. Cell Biol. 2004, 24(7):2627-2636.
42. Golks A., et al. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J. Exp. Med. 2006, 203(5):1295-1305.
43. Misra R.S., et al. Caspase-8 and c-FLIPL associate in lipid rafts with NF-kappaB adaptors during T cell activation. J. Biol. Chem. 2007, 282(27):19365-19374.
44. Ueffing N., et al. Up-regulation of c-FLIP short by NFAT contributes to apoptosis resistance of short-term activated T cells. Blood 2008, 112(3):690-698.
45. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect Biol. 2009, 1(5):a000141.
46. Lee J.S., et al. FLIP-mediated autophagy regulation in cell death control. Nat. Cell Biol. 2009, 11(11):1355-1362.
47. Panner A., et al. MTOR-independent translational control of the extrinsic cell death pathway by RalA. Mol. Cell Biol. 2006, 26(20):7345-7357.
48. Katayama R., et al. Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L. J. Cell Sci. 2010, 123(Pt 1):23-28.
49. Quintavalle C., et al. C-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3beta activity. Cell Death Differ. 2010, 17(12):1908-1916.
50. Yalcin S., et al. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. EMBO J. 2010, 29(24):4118-4131.
51. Skurk C., et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J. Biol. Chem. 2004, 279(2):1513-1525.
52. Iyer A.K., et al. Role of S-nitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide 2008, 19(2):146-151.
53. Clement M.V., Pervaiz S. Intracellular superoxide and hydrogen peroxide concentrations: a critical balance that determines survival or death. Redox. Report 2001, 6(4):211-214.
54. Clement M.V., Ponton A., Pervaiz S. Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. Febs Lett. 1998, 440(1-2):13-18.
55. Pervaiz S. Pro-oxidant milieu blunts scissors: insight into tumor progression, drug resistance, and novel druggable targets. Curr. Pharm. Des. 2006, 12(34):4469-4477.
56. Pervaiz S., Clement M.V. A permissive apoptotic environment: function of a decrease in intracellular superoxide anion and cytosolic acidification. Biochem. Biophys. Res. Commun. 2002, 290(4):1145-1150.
57. Pervaiz S., Clement M.V. Hydrogen peroxide-induced apoptosis: oxidative or reductive stress?. Redox. Cell Biol. Genet., Part A 2002, 352:150-159.
58. Pervaiz S., Clement M.V. Superoxide anion: oncogenic reactive oxygen species?. Int. J. Biochem. Cell Biol. 2007, 39(7-8):1297-1304.
59. Pervaiz S., et al. Superoxide anion inhibits drug-induced tumor cell death. Febs Lett. 1999, 459(3):343-348.
60. Clement M.V., Hirpara J.L., Pervaiz S. Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ. 2003, 10(11):1273-1285.
61. Pervaiz S., et al. Activation of the RacGTPase inhibits apoptosis in human tumor cells. Oncogene 2001, 20(43):6263-6268.
62. Poh T.W., et al. LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ. 2007, 14(10):1813-1825.
63. Poh T.W., Pervaiz S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-akt pathway. Cancer Res. 2005, 65(14):6264-6274.
64. Kumar A.P., et al. Oxidative repression of NHE1 gene expression involves iron-mediated caspase activity. Cell Death Differ. 2007, 14(10):1733-1746.
65. Feoktistova M., et al. CIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 2011, 43(3):449-463.
66. Bertrand M.J., Vandenabeele P. The Ripoptosome: death decision in the cytosol. Mol. Cell 2011, 43(3):323-325.